Superiority of bivalirudin over heparin anticoagulation therapy for extracorporeal membrane oxygenation? Too early to draw conclusions
Background: We aimed to compare the efficacy and safety of bivalirudin versus heparin as the anticoagulant in patients undergoing extracorporeal membrane oxygenation (ECMO). Methods: We conducted a search in PubMed, Embase and the Cochrane Library for all the studies in which bivalirudin was compare...
Main Authors: | Jie Gu, Hongjie Yu, Dang Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-02-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023007375 |
Similar Items
-
Is it time to switch to bivalirudin for ECMO anticoagulation?
by: Amir Navaei, et al.
Published: (2023-08-01) -
Bivalirudin for cardiac catheterization in a pediatric patient with religious objection to the use of porcine-derived heparin
by: A. Caskey, et al.
Published: (2021-08-01) -
Bivalirudin for cardiopulmonary bypass in a patient with heparin allergy
by: Emre Boysan, et al.
Published: (2023-09-01) -
Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review
by: Carlos A. Valdes, et al.
Published: (2023-03-01) -
Anticoagulation strategies in COVID-19 infected patients receiving ECMO support
by: Diaz Dayne, et al.
Published: (2023-09-01)